Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Hills Bank & Trust Co

Hills Bank & Trust Co lessened its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.6% during the fourth quarter, HoldingsChannel reports. The firm owned 5,418 shares of the medical equipment provider’s stock after selling 143 shares during the quarter. Hills Bank & Trust Co’s holdings in Intuitive Surgical were worth $2,828,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Atala Financial Inc purchased a new position in Intuitive Surgical during the fourth quarter worth about $25,000. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter valued at about $26,000. BankPlus Trust Department purchased a new position in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth approximately $31,000. Finally, MidAtlantic Capital Management Inc. acquired a new stake in shares of Intuitive Surgical in the third quarter worth approximately $33,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 269 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $590.00, for a total transaction of $158,710.00. Following the sale, the chief financial officer now owns 3,282 shares in the company, valued at $1,936,380. This represents a 7.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Fredrik Widman sold 810 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $573.78, for a total value of $464,761.80. Following the transaction, the vice president now directly owns 473 shares in the company, valued at approximately $271,397.94. This represents a 63.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock worth $17,691,621 in the last ninety days. 0.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. BTIG Research increased their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Raymond James increased their target price on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Stifel Nicolaus lifted their target price on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Royal Bank of Canada upped their price target on Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. Finally, CICC Research started coverage on Intuitive Surgical in a research note on Monday, January 27th. They issued a “neutral” rating and a $550.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Stock Up 1.6 %

Shares of ISRG opened at $484.44 on Friday. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The firm has a market cap of $172.55 billion, a price-to-earnings ratio of 75.58, a PEG ratio of 5.85 and a beta of 1.43. The business’s 50 day moving average is $567.46 and its two-hundred day moving average is $531.26.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.